Industries > Pharma > Psoriasis Treatment: World Drug Market 2013-2023

Psoriasis Treatment: World Drug Market 2013-2023

PUBLISHED: 05 September 2013
PAGES: 156
PRODUCT CODE:
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: N/A Categories: ,

Psoriasis drugs – this new study shows you R&D, opportunities, and potential revenues

What's the future of treating psoriasis? Visiongain's new report gives you revenue predictions from 2013, helping you stay ahead. There you see financial results, R&D trends, opportunities, and potential revenues.

Avoid falling behind, then, missing business or losing influence. In our new report you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess technologies, competitive forces and expected products.

Read on to explore that industry and see what its future market could be worth.

Forecasts from 2013-2023 and other analyses to help you harness opportunities

Besides revenue forecasting to 2023, our new work shows recent results, growth rates, and market shares. There you discover original analysis, seeing commercial outlooks and developments (R&D). You also get 73 tables, 62 charts, and two interviews.

Gains through knowledge on psoriasis medicines – discover advantages for your work

Why miss data you need? Why struggle to find it? Instead let our analysis guide you through that market's present and future. That understanding could bring you quicker, easier results. Also you gain expertise to show your authority on those dermatological treatments.

Leaders hold knowledge. Use our predictions, then, to help expand your business and give you more influence. Avoid falling behind. Instead try our new report now.

There you hear what's happening in the industry for psoriasis treatments. You also see where needs and money lie from 2013 to 2023, finding how you and your organisation can gain.

The following sections show what you get in that new investigation.

Sales predictions for the world market and submarkets

What're the secrets of that industry's progress and what's its potential? Discover in our report overall world revenue to 2023 for psoriasis treatment by drugs. Also find individual revenue forecasts to 2023 for therapeutic submarkets at world level:
• Biologics (biological drugs)
• Topical treatments
• Small-molecule systemic agents.

How will those markets expand? Which classes of treatment will generate most money? There you assess prospects for revenue growth, seeing where you can gain.

You find sales predictions by product, too, getting feel for how they can succeed.

Revenue predictions for 10 leading products and 4 expected therapies

How will individual drugs perform from 2013 to 2023 at world level? Our report forecasts psoriasis-treating revenues of 10 established brands and four expected medicines. Assess products such as these:
• Humira
• Enbrel
• Stelara
• Remicade
• Apremilast
• Secukinumab
• Ixekizumab.

There discover how high sales can go, to 2023, finding drugs and years with highest predicted growth and revenues. Also you examine competition. You see what's happening there, understanding challenges, trends, competitors, and opportunities.

You find geographical revenue predictions too.

National markets – where will highest revenues and growth occur?

In developed and developing countries, opportunities for pharma companies in psoriasis treatment will occur from 2013. You see where and how.

Our analyses show individual revenue forecasts to 2023 for 11 national markets:
• US
• Japan
• Germany, France, UK, Italy, and Spain (EU5)
• Brazil, Russia, India, and China (BRIC).

There you find countries with highest revenues and potential sales growth. Our work explains. You assess that technology's future, seeing progress and finding what it means, including emerging trends for those medicines.

Events affecting developers, producers, and sellers

The report explains forces affecting that industry and market from 2013, including these:
• Research and development, including that for monoclonal antibodies (mAbs), IL-17, IL-23, TNF, JAK, and CD4 T-cell inhibition, and anti-inflammatory therapy
• Prevalence and causes of that disease, as well as issues for patient populations
• Competition from generic drugs (generics) and novel therapies
• Companies specialising in dermatology – capabilities and emerging trends
• Demands for better treatments – how payers and the industry respond
• Advances in topical drug delivery.

There you explore political, economic, social, and technological questions, assessing advances and outlooks for business. Discover what the present and future hold.

Companies leading that industry and its market value in 2018

From 2013, treatments for that disorder hold potential for investments, medical advances, and higher revenues. Our work predicts the world market for the psoriasis indication will reach $8.9bn in 2018 – rising from $6bn in 2012 – with further expansion to 2023.

See what's possible there – the expected gains. Our report shows you what technologies and players hold greatest potential. In particular, you explore activities of these companies:
• AbbVie
• Johnson & Johnson (J&J)
• Amgen
• Pfizer
• LEO Pharma
• GlaxoSmithKline (GSK)
• Merck & Co.
• Novartis
• Celgene
• Eli Lilly.

Our analysis shows you participants' results, capabilities, and outlooks. Prospects for R&D in that industry are strong, and from 2013 it holds many opportunities for revenue growth. Our work explains that potential, helping you stay ahead.

Information found nowhere else

In particular, then, our new investigation gives you these advantages:
• Revenues to 2023 at world level, with forecasting of 3 submarkets and 14 products – assess prospects for investments and sales
• Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia – investigate countries for revenues and expected growth
• Prospects for established competitors, rising companies, and new entrants – explore portfolios, results, R&D activities, and outlooks for future success.

Psoriasis Treatment: World Drug Market 2013-2023 gives independent analysis. There you receive business intelligence found only in our work, finding where money lies.

With that report you are less likely to fall behind in knowledge or miss sales opportunity. See there how you could benefit your research, analysis, and decisions. Explore progress and possibilities. Also find how you can save time and get recognition for insight.

Medicines for psoriasis – assess their potentials now, seeing what you can gain

Our new report is for everyone investigating drugs for inflammation and skin disorders. There you see revenue forecasts to 2023, with discussions. Avoid missing out – please order now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

To view free sample pages of this report please click here

Download sample pages

Complete the form below to download your free sample pages for Psoriasis Treatment: World Drug Market 2013-2023


Download sample pages

Complete the form below to download your free sample pages for Psoriasis Treatment: World Drug Market 2013-2023


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories